Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Telix Pharmaceuticals Limited

Biotech Giants' Revenue Costs: A Decade of Divergence

__timestampNeurocrine Biosciences, Inc.Telix Pharmaceuticals Limited
Wednesday, January 1, 20141440000022622695
Thursday, January 1, 20153380000024863028
Friday, January 1, 20163590000021351001
Sunday, January 1, 2017125400053837297
Monday, January 1, 2018488900016080096
Tuesday, January 1, 2019740000018525736
Wednesday, January 1, 2020101000002024000
Friday, January 1, 2021143000002548000
Saturday, January 1, 20222320000061556000
Sunday, January 1, 202339700000188157000
Monday, January 1, 202434000000
Loading chart...

Unleashing the power of data

Cost of Revenue: A Tale of Two Biotech Giants

In the ever-evolving world of biotechnology, understanding the cost of revenue is crucial for assessing a company's financial health. Neurocrine Biosciences, Inc. and Telix Pharmaceuticals Limited, two prominent players in the industry, have shown contrasting trends over the past decade. From 2014 to 2023, Neurocrine's cost of revenue has seen a steady increase, peaking in 2023 with a 175% rise from its 2014 figures. Meanwhile, Telix Pharmaceuticals experienced a more volatile journey, with a staggering 730% increase in 2023 compared to 2014. This dramatic rise highlights Telix's aggressive expansion and investment in its product pipeline. The data reveals a fascinating narrative of strategic growth and financial management, offering valuable insights for investors and industry analysts alike. As these companies continue to innovate, their cost of revenue will remain a key indicator of their operational efficiency and market strategy.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025